Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE tria

Aims It is uncertain whether the benefit from apixaban varies by type and duration of atrial fibrillation (AF).

Methods and results A total of 18 201 patients with AF [2786 (15.3%) with paroxysmal and 15 412 (84.7%) with persistent or permanent] were randomized to apixaban or warfarin. In this pre-specified secondary analysis, we compared outcomes and treatment effect of apixaban vs. warfarin by AF type and duration. The primary efficacy endpoint was a composite of ischaemic or haemorrhagic stroke or systemic embolism.  Read more